A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa (NCT07287644)
A Phase 2, Dose Ranging, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of BFB759 in Patients With Moderate to Severe Hidradenitis Suppurativa
🩺 Plain-English Summary (8th-Grade Level)
This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.
Who can join: Review the eligibility criteria below.
Location: Saguaro Dermatology — Phoenix, Arizona
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (58 Sites)
Showing the first 25 of 58 sites.
- Saguaro Dermatology — Phoenix, Arizona
- Encino Research Center — Encino, California
- Clinical Science Institute — Santa Monica, California
- Skin Care Research — Boca Raton, Florida
- Center for Skin Science and Innovation — Fort Lauderdale, Florida
- Ziaderm Research LLC — North Miami Beach, Florida
- Clinical Trials Management, LLC — Tampa, Florida
- DelRicht Research — Atlanta, Georgia
- Southeast Research Specialist LLC — Douglasville, Georgia
- The Indiana Clinical Trials Center, PC — Plainfield, Indiana
- DS Research of Kentucky — Louisville, Kentucky
- Martha Stewart — Mandeville, Louisiana
- Clinical Trials Management, LLC — Metairie, Louisiana
- DelRicht Research — New Orleans, Louisiana
- Oakland Hills Dermatology — Auburn Hills, Michigan
- MI Skin Innovations — Northville, Michigan
- DelRicht Research — Wildwood, Missouri
- JDR Dermatology Research LLC — Las Vegas, Nevada
- Skin Cancer and Dermatology Institute — Reno, Nevada
- Schweiger Dermatology, PC — Hackensack, New Jersey
- Equity Medical LLC — The Bronx, New York
- Optima Research - Boardman — Boardman, Ohio
- Apex Clinical Research Center, LLC — Canton, Ohio
- Apex Clinical Research Center, LLC — Mayfield Heights, Ohio
- UPMC Department of Dermatology — Pittsburgh, Pennsylvania
📞 Contact the Study Coordinator
Phone: (214) 728-6505
Email: Reichelkraut@bluefinbiomed.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hidradenitis Suppurativa (HS)
- Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense — Phoenix, Arizona
- A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa — Phoenix, Arizona
- Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa — Missouri City, Texas
- A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial) — Irvine, California
- A Study to Evaluate the Efficacy of Botulinum Toxin in Patients With Hidradenitis Suppurativa — Worcester, Massachusetts
- ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa — Chapel Hill, North Carolina
Explore by condition: All Hidradenitis Suppurativa (HS) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.